ABBV Today - Aug 09: Mixed signals on revenue

カートのアイテムが多すぎます

ご購入は五十タイトルがカートに入っている場合のみです。

カートに追加できませんでした。

しばらく経ってから再度お試しください。

ウィッシュリストに追加できませんでした。

しばらく経ってから再度お試しください。

ほしい物リストの削除に失敗しました。

しばらく経ってから再度お試しください。

ポッドキャストのフォローに失敗しました

ポッドキャストのフォロー解除に失敗しました

ABBV Today - Aug 09: Mixed signals on revenue

無料で聴く

ポッドキャストの詳細を見る

Hey there! It’s Joey here, your friendly longtime investor, breaking down today’s stock action. We’re talking about AbbVie, and it was a pretty chill day — the stock was up just a smidge, about 0.9%.

So, here’s the scoop. AbbVie started the day with some good vibes but ended up kinda flat. It bounced around a bit but didn’t really make any big moves. There were a few things stirring the pot, but nothing that really sent it soaring or crashing.

Now, let’s get into the why of it all. One article pointed out that AbbVie’s Rinvoq is expanding its reach in Europe, which is generally a good look for the company. But then there was a buzzkill — they raised their 2026 revenue outlook and issued new debt, which sent the stock down about 5.3% earlier this week. Yeah, that one stung. Investors are always a bit jittery about debt, and it seems like that’s what happened here. So, mixed signals all around.

Also, there’s chatter comparing AbbVie to Abbott Laboratories, which is another healthcare stock. Some folks are weighing which one’s the better buy in 2026. That’s interesting, but honestly, it's just more noise in the background right now.

Oh, and something worth keeping an eye on: AbbVie’s dividend game is still strong, and they’ve been mentioned as one of the top picks for dividends right now. That’s a nice little perk if you’re holding onto the stock.

So, to wrap it up, AbbVie had a day where it kinda just waddled along, with some good news about Rinvoq but also some worries over debt. Just another day in the stock market, right? Remember, this is just for your info and entertainment, not financial advice. Catch you later!

まだレビューはありません